Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Ventilator project - OxVent - gets green light by UK government to proceed to next stage of testing

OxVent is a multidisciplinary team of engineers and medics at the University of Oxford and King’s College London. The team has been shortlisted by the UK government to go to the next stage of testing for safety and usability for their ventilator prototype.

First patients enrolled in new clinical trial of possible COVID-19 treatments

Researchers from the University of Oxford have launched a new clinical trial to test the effects of potential drug treatments for patients admitted to hospital with COVID-19. The first patients have now been recruited.

COVID-19's impact on youth mental health the focus of new research

COVID-19 has led to an elevated awareness of threat in the environment and has caused major disruptions to families’ lives, through social distancing, school closures, and now effective lock-down. A new research survey, launched today from experts at the University of Oxford, will track children and young people’s mental health throughout the COVID-19 crisis to identify what advice, support and help can actually protect their mental health.

GP practices urged to join COVID-19 research

Today, the Oxford RCGP’s Research and Surveillance Centre (RSC) has written to nearly 4,000 GP practices in England using EMIS Health systems asking them to contribute patient data to help them develop a deeper understanding of the COVID-19 pandemic in general practice.

Bayer-Oxford Alliance for Women’s Health


Marie-Laetitia Thezenas et al from the Kessler group in collaboration with NDORMS and Bayer shows in a very elegant, combined proteomics and transcriptomic study the relevance of AOC3 / VAP1 for oxidative stress and inflammation in endometriosis.

Nobel Prize for Medicine awarded to NDM Professor Sir Peter Ratcliffe

Peter Ratcliffe, William Kaelin and Gregg Semenza share the 2019 Nobel Prize for or Physiology and Medicine. They discovered how cells sense and adapt to oxygen levels, findings that affect our day-to-day life from exercise, to being at high altitudes to our early development in the womb. Their work is leading to new treatments for anaemia and even cancer

Research identifies how the gut loses protective barrier function in IBD

A single-cell based study from Prof Alison Simmons Lab describes clonic epithelial cell diversity in health and inflammatory bowel disease (IBD).

Big Data Institute announces two new research alliances

The Big Data Institute (BDI) has recently announced new research alliances with Novartis and Sensyne Health.

Oxford secures £17.5 million to lead national programmes in AI to improve healthcare

Funding will be provided to the University of Oxford through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments.

Novel cancer treatment resistance mechanism uncovered

BRCA1 deficiencies cause breast and ovarian cancer, rendering tumours hypersensitive to PARP inhibitors. Patient treatment can become ineffective due to emerging resistance mechanisms. Ross Chapman’s team at the Welcome Centre has uncovered a protein complex termed Shieldin that acts with 53BP1 to limit end resection at DNA double-strand breaks, which confers resistance to cancer treatment.

Biomarker discovery for patients with malignant pleural effusion

Ioannis Psallidas (Respiratory Medicine) and colleagues including members of the Target Discovery Institute (TDI) (Benedikt Kessler / Roman Fischer) have developed a score that predicts risk of death for a common metastasis of patients with malignant pleural effusion.

FORMA Therapeutics and the University of Oxford Announce Multi-Year Cross-Border Collaboration

The FORMA/Oxford collaboration brings together Oxford’s expertise in disease molecular pathology and Ubiquitin biology, (including through the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI), the Target Discovery Institute (TDI) and the Oxford Parkinson’s Disease Centre (OPDC)), and FORMA’s deep expertise in small molecule drug design and development.

Scientists discover promising ‘off-switch’ for inflammatory diseases

Researchers in Ireland, the UK and US have discovered a new metabolic process in the body that can switch off inflammation. “itaconate” – a molecule derived from glucose – “acts as a powerful off switch for macrophages”, thereby reducing inflammation.

The Journey from Genes to Disease – a symposium for postdocs by postdocs

A free one day symposium, to be held on 20 April 2018, Medical Sciences Training Centre, Oxford and organised by the Postdoctoral Training Fellows at MRC Harwell Institute. The theme is the influence of genetics and genetic regulation in modelling human disease – from molecular through cellular to whole animal level and encompassing developmental, environmental and behavioural interactions.

Oxford one of six sites to receive funding for health data science

Health Data Research UK is awarding £30 million funding to six sites across the UK, including the University of Oxford, to address challenging healthcare issues through use of data science.

New Year's Honours 2018

Congratulations to Professor Chas Bountra, Professor of Translational Medicine at the Nuffield Department of Medicine, who has been appointed OBE for services to Translational Medical Research in the New Year's Honours List 2018. Congratulations also to Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) who has been appointed MBE for services to Clinical Research.

Global health needs demand new approach to drug discovery

Professor Chas Bountra, Co-Director of the Oxford Martin Programme on Affordable Medicines and Chief Scientist at the Structural Genomics Consortium, explains why a new approach to drug discovery and development is needed to address the urgent need for new drugs.

New structural insights accelerate drug discovery in the ubiquitin system for cancer therapy

Modern cancer therapies often rely on the specific targeting of mutated proteins by small molecules that interfere with their function. However, some of these proteins which drive cancer are difficult to target directly. To get round this problem, scientists have tapped into the ubiquitin-proteasome system (UPS) which controls the stability of client proteins. Their findings are published in Nature today (18th October 2017).

Professor Sir Peter Ratcliffe awarded Royal Society Buchanan Medal

The Royal Society has awarded Professor Sir Peter Ratcliffe, Director of the Target Discovery Institute at the University of Oxford and Clinical Research Director at the Francis Crick Institute, with the Buchanan Medal for his ground-breaking research on oxygen sensing and signalling pathways mediating cellular responses to low oxygen levels or 'hypoxia'.

Load More